BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26567765)

  • 1. The presence of genomic imbalances is associated with poor outcome in patients with burkitt lymphoma treated with dose-intensive chemotherapy including rituximab.
    Forero-Castro M; Robledo C; Lumbreras E; Benito R; Hernández-Sánchez JM; Hernández-Sánchez M; García JL; Corchete-Sánchez LA; Tormo M; Barba P; Menárguez J; Ribera J; Grande C; Escoda L; Olivier C; Carrillo E; García de Coca A; Ribera JM; Hernández-Rivas JM
    Br J Haematol; 2016 Feb; 172(3):428-38. PubMed ID: 26567765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose-intensive chemotherapy including rituximab in Burkitt's leukemia or lymphoma regardless of human immunodeficiency virus infection status: final results of a phase 2 study (Burkimab).
    Ribera JM; García O; Grande C; Esteve J; Oriol A; Bergua J; González-Campos J; Vall-Llovera F; Tormo M; Hernández-Rivas JM; García D; Brunet S; Alonso N; Barba P; Miralles P; Llorente A; Montesinos P; Moreno MJ; Hernández-Rivas JÁ; Bernal T
    Cancer; 2013 May; 119(9):1660-8. PubMed ID: 23361927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.
    Thomas DA; Faderl S; O'Brien S; Bueso-Ramos C; Cortes J; Garcia-Manero G; Giles FJ; Verstovsek S; Wierda WG; Pierce SA; Shan J; Brandt M; Hagemeister FB; Keating MJ; Cabanillas F; Kantarjian H
    Cancer; 2006 Apr; 106(7):1569-80. PubMed ID: 16502413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
    Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
    AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment outcome of adult patients with Burkitt lymphoma: results using the LMB protocol in Korea.
    Choi MK; Jun HJ; Lee SY; Kim KH; Lim DH; Kim K; Ko YH; Kim WS; Kim SJ
    Ann Hematol; 2009 Nov; 88(11):1099-106. PubMed ID: 19288103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormalities on 1q and 7q are associated with poor outcome in sporadic Burkitt's lymphoma. A cytogenetic and comparative genomic hybridization study.
    García JL; Hernandez JM; Gutiérrez NC; Flores T; González D; Calasanz MJ; Martínez-Climent JA; Piris MA; Lopéz-Capitán C; González MB; Odero MD; San Miguel JF
    Leukemia; 2003 Oct; 17(10):2016-24. PubMed ID: 14513052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.
    Oriol A; Ribera JM; Bergua J; Giménez Mesa E; Grande C; Esteve J; Brunet S; Moreno MJ; Escoda L; Hernandez-Rivas JM; Hoelzer D
    Cancer; 2008 Jul; 113(1):117-25. PubMed ID: 18457327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
    Wagener R; Seufert J; Raimondi F; Bens S; Kleinheinz K; Nagel I; Altmüller J; Thiele H; Hübschmann D; Kohler CW; Nürnberg P; Au-Yeung R; Burkhardt B; Horn H; Leoncini L; Jaffe ES; Ott G; Rymkiewicz G; Schlesner M; Russell RB; Klapper W; Siebert R
    Blood; 2019 Feb; 133(9):962-966. PubMed ID: 30567752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Stratification of Patients with Burkitt Lymphoma Using Serum β2-microglobulin Levels.
    Kim HD; Cho H; Kim S; Lee K; Kang EH; Park JS; Park CS; Huh J; Ryu JS; Lee SW; Yoon DH; Kim SJ; Ko YH; Kim WS; Suh C
    Cancer Res Treat; 2021 Jul; 53(3):847-856. PubMed ID: 33332932
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Submicroscopic genomic imbalances in Burkitt lymphomas/leukemias: association with age and further evidence that 8q24/MYC translocations are not sufficient for leukemogenesis.
    Lundin C; Hjorth L; Behrendtz M; Ehinger M; Biloglav A; Johansson B
    Genes Chromosomes Cancer; 2013 Apr; 52(4):370-7. PubMed ID: 23225516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensive short-term chemotherapy regimen induces high remission rate (over 90%) and event-free survival both in children and adult patients with advanced sporadic Burkitt lymphoma/leukemia.
    Todeschini G; Bonifacio M; Tecchio C; Balter R; Carli G; Stefani PM; Adami F; Zamò A; Dei Tos AP; Marino F; Gherlinzoni F; Marradi P; Semenzato G; Pizzolo G
    Am J Hematol; 2012 Jan; 87(1):22-5. PubMed ID: 22086870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Intensive chemotherapy for Burkitt lymphoma in HIV positive patients].
    Puga L B; Bustamante K K; Molina E J; Andrade M A
    Rev Med Chil; 2015 Dec; 143(12):1505-11. PubMed ID: 26928610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burkitt Lymphoma International Prognostic Index.
    Olszewski AJ; Jakobsen LH; Collins GP; Cwynarski K; Bachanova V; Blum KA; Boughan KM; Bower M; Dalla Pria A; Danilov A; David KA; Diefenbach C; Ellin F; Epperla N; Farooq U; Feldman TA; Gerrie AS; Jagadeesh D; Kamdar M; Karmali R; Kassam S; Kenkre VP; Khan N; Kim SH; Klein AK; Lossos IS; Lunning MA; Martin P; Martinez-Calle N; Montoto S; Naik S; Palmisiano N; Peace D; Phillips EH; Phillips TJ; Portell CA; Reddy N; Santarsieri A; Sarraf Yazdy M; Smeland KB; Smith SE; Smith SD; Sundaram S; Zayac AS; Zhang XY; Zhu C; Cheah CY; El-Galaly TC; Evens AM
    J Clin Oncol; 2021 Apr; 39(10):1129-1138. PubMed ID: 33502927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Burkitt post-transplantation lymphoma in adult solid organ transplant recipients: sequential immunochemotherapy with rituximab (R) followed by cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or R-CHOP is safe and effective in an analysis of 8 patients.
    Zimmermann H; Reinke P; Neuhaus R; Lehmkuhl H; Oertel S; Atta J; Planker M; Gärtner B; Lenze D; Anagnostopoulos I; Riess H; Trappe RU
    Cancer; 2012 Oct; 118(19):4715-24. PubMed ID: 22392525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Outcome of children and adolescents with Burkitt lymphoma and diffuse large B cell lymphoma treated with a modified NHL-BFM-90 protocol].
    Sun XF; Zhen ZJ; Xia Y; Lin SX; Zhu J; Wang J; Lu SY; Sun FF; Chen Y; Zhang F; Cai RQ; Li PF
    Zhonghua Xue Ye Xue Za Zhi; 2013 Dec; 34(12):1032-7. PubMed ID: 24369160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21.
    Scandurra M; Mian M; Greiner TC; Rancoita PM; De Campos CP; Chan WC; Vose JM; Chigrinova E; Inghirami G; Chiappella A; Baldini L; Ponzoni M; Ferreri AJ; Franceschetti S; Gaidano G; Montes-Moreno S; Piris MA; Facchetti F; Tucci A; Nomdedeu JF; Lazure T; Lambotte O; Uccella S; Pinotti G; Pruneri G; Martinelli G; Young KH; Tibiletti MG; Rinaldi A; Zucca E; Kwee I; Bertoni F
    Br J Haematol; 2010 Nov; 151(3):221-31. PubMed ID: 20813005
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of MYC rearrangement in cases of B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma.
    Lin P; Dickason TJ; Fayad LE; Lennon PA; Hu P; Garcia M; Routbort MJ; Miranda R; Wang X; Qiao W; Medeiros LJ
    Cancer; 2012 Mar; 118(6):1566-73. PubMed ID: 21882178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose-intensive chemotherapy including rituximab is highly effective but toxic in human immunodeficiency virus-infected patients with Burkitt lymphoma/leukemia: parallel study of 81 patients.
    Xicoy B; Ribera JM; Müller M; García O; Hoffmann C; Oriol A; Hentrich M; Grande C; Wasmuth JC; Esteve J; van Lunzen J; Del Potro E; Knechten H; Brunet S; Mayr C; Escoda L; Schommers P; Alonso N; Vall-Llovera F; Pérez M; Morgades M; González J; Fernández A; Thoden J; Gökbuget N; Hoelzer D; Fätkenheuer G; Wyen C;
    Leuk Lymphoma; 2014 Oct; 55(10):2341-8. PubMed ID: 24397614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential karyotyping in Burkitt lymphoma reveals a linear clonal evolution with increase in karyotype complexity and a high frequency of recurrent secondary aberrations.
    Aukema SM; Theil L; Rohde M; Bauer B; Bradtke J; Burkhardt B; Bonn BR; Claviez A; Gattenlöhner S; Makarova O; Nagel I; Oschlies I; Pott C; Szczepanowski M; Traulsen A; Kluin PM; Klapper W; Siebert R; Murga Penas EM
    Br J Haematol; 2015 Sep; 170(6):814-25. PubMed ID: 26104998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.